Relationship between body surface area and ALT normalization after long-term lamivudine treatment

Table 1 Baseline characteristics of patients treated for 1 year¹

	Total (range)	SR-ALT	NR-ALT	SR-DNA	NR-DNA
n	249	150	99	183	66
Male/female	180/67	99/51	82/17	127/54	53/13
ALT (U/L)	211.1±402.4 (16-4491)	242.1±424.2	163.6±363.6	240.3±462.2	128.8±88.1
Albumin (g/dL)	3.8±0.6 (2.2-4.9)	3.8±0.6	3.8±0.6	3.8±0.6	3.9±0.6
Bilirubin (mg/dL)	1.3±1.7 (0.1-12.9)	1.4±1.8	1.2±1.5	1.4±1.9	1.0±1.1
Platelet (104/mL)	14.1±6.1 (2.6-35.5)	14.2±5.8	14.0±6.5	13.9±6.2	14.9±5.6
BSA (m2)	1.70±0.20 (1.25-2.17)	1.66±0.17	1.75±0.18	1.69±0.18	1.73±0.18
HBV-DNA
≤5 (LEG/mL)	31	20	11	29	2
5< ≤6	33	18	15	27	6
6< ≤7	68	41	27	52	16
7<	117	71	46	75	42
HBeAg +/–	135/110	83/64	52/46	84/96	51/14
Age (yr)	48.6±11.6 (19-73)
CH/LC [Child A/B/C]	162/87 [61/11/15]

¹Data are shown as mean±SD.